RPG Life Sciences board meeting scheduled for April 29, 2026 to approve audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026.
Board will consider recommending dividend, if any, on equity shares for financial year ended March 31, 2026.
Trading window for designated persons closed from April 1, 2026 and will remain closed until 48 hours after results declaration on April 29, 2026.